EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Chordate Medical Holding AB's Enterprise Value is €-0.39 Mil.
Chordate Medical Holding AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was €-2.31 Mil. Therefore, Chordate Medical Holding AB's EV-to-FCF for today is 0.17.
The historical rank and industry rank for Chordate Medical Holding AB's EV-to-FCF or its related term are showing as below:
FRA:K1Z'
s EV-to-FCF Range Over the Past 10 Years
Min: -2199.33 Med: -1.04 Max: 0.15
Current: 0.15
During the past 10 years, the highest EV-to-FCF of Chordate Medical Holding AB was 0.15. The lowest was -2199.33. And the median was -1.04.
FRA:K1Z's EV-to-FCF is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 22.52
vs FRA:K1Z: 0.15
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chordate Medical Holding AB (FRA:K1Z) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chordate Medical Holding AB's PE Ratio (TTM) for today is calculated as:
Chordate Medical Holding AB's share price for today is €0.001.
Chordate Medical Holding AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Chordate Medical Holding AB EV-to-FCF Related Terms
Chordate Medical Holding AB EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Chordate Medical Holding AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chordate Medical Holding AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Chordate Medical Holding AB's EV-to-FCF falls into.
Chordate Medical Holding AB's current Enterprise Value is €-0.39 Mil.
Chordate Medical Holding AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chordate Medical Holding AB (FRA:K1Z) has a EV-to-FCF of 0.17 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Chordate Medical Holding AB and its competitors.
Is Chordate Medical Holding AB's EV-to-FCF too high?
Chordate Medical Holding AB's current EV-to-FCF is 0.17. The Medical Devices & Instruments industry median EV-to-FCF is 22.52. Chordate Medical Holding AB's value of 0.17 is 99.2% below this industry median. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's EV-to-FCF compare to ABT and SYK?
Chordate Medical Holding AB's EV-to-FCF of 0.17 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-FCF is 22.52. Chordate Medical Holding AB's value of 0.17 is 99.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.52, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chordate Medical Holding AB's current EV-to-FCF of 0.17 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Chordate Medical Holding AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chordate Medical Holding AB's current EV-to-FCF is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (FRA:K1Z) has a current EV-to-FCF of 0.17. The stock's GF Value™ is €0.16, compared to a current price of €0.00 — trading 99.4% below its estimated fair value. The current EV-to-FCF is 0.17 and 99.2% below the Medical Devices & Instruments industry median of 22.52. Chordate Medical Holding AB's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Chordate Medical Holding AB (FRA:K1Z), the current EV-to-FCF is 0.17 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chordate Medical Holding AB (FRA:K1Z) Overvalued in 2026?
Based on GuruFocus' analysis, Chordate Medical Holding AB stock appears to be undervalued.
The current stock price of €0.00 is trading 99.4% below its estimated GF Value™ of €0.16.
Key valuation signals for FRA:K1Z:
EV-to-FCF: 0.17
GF Value™: €0.16 vs. price of €0.00 (99.4% below fair value)
Industry Position: 99.2% below the Medical Devices & Instruments median
No single metric tells the full story. See the FRA:K1Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score
Get the complete analysis for FRA:K1Z
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:K1Z has been successfully added to your 
